Free Republic 4th Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $20,895
25%  
Woo hoo!! And we're now over 25%!! Thank you all very much!! God bless.

Keyword: drugsafety

Brevity: Headers | « Text »
  • Elena Kagan's First Vote Was Both Baffling and Predictable

    12/11/2010 11:40:04 AM PST · by jazusamo · 23 replies
    American Thinker ^ | December 11, 2010 | Anthony W. Hager
    Once Elena Kagan was confirmed to the Supreme Court it was certain that she would, at some point, cast a vote or render an opinion. It sort of goes with the territory. Of near equal certainty was that her initial ruling would embody everything objectionable and inexplicable about the Supreme Court, judges, lawyers, and the legal system in general. Well, Justice Kagan has cast that first vote, to little fanfare I might add. In so doing she proved that my confidence in her ability to baffle was justified. Granted, Kagan's first decision wasn't a thorough legal dissertation. It was...
  • China: Tainted Drugs Linked to Maker of Abortion Pill (Shanghai Hualian’s RU-486)

    01/31/2008 3:25:50 AM PST · by TigerLikesRooster · 3 replies · 76+ views
    NYT ^ | 01/31/08 | JAKE HOOKER and WALT BOGDANICH
    Tainted Drugs Linked to Maker of Abortion Pill By JAKE HOOKER and WALT BOGDANICH BEIJING — A huge state-owned Chinese pharmaceutical company that exports to dozens of countries, including the United States, is at the center of a nationwide drug scandal after nearly 200 Chinese cancer patients were paralyzed or otherwise harmed last summer by contaminated leukemia drugs. Chinese drug regulators have accused the manufacturer of the tainted drugs of a cover-up and have closed the factory that produced them. In December, China’s Food and Drug Administration said that the Shanghai police had begun a criminal investigation and that two...
  • FDA Panel: Celebrex Should Stay on Market

    02/18/2005 12:16:45 PM PST · by freespirited · 5 replies · 269+ views
    AP ^ | 2/17/05 | RANDOLPH E. SCHMID
    WASHINGTON - Advisers to the Food and Drug Administration (news - web sites) concluded Friday the popular painkiller Celebrex poses an increased risk for heart problems but should remain on the market because the benefits outweigh the dangers. The panelists suggested a number of possible restrictions, including placing a "black box" warning on the label warning of the potential dangers and who's at risk, providing more patient information with the drug, restricting which patients could get it and banning direct-to-consumer advertising for Celebrex. The FDA is not bound to follow any of the recommendations. If it does decide to keep...